🔴 HIMS is trading 6.6% down today on Q1 earnings miss and branded GLP-1 margin concerns

HIMS is trading at $23.39 (-6.55%), extending a sharp post-earnings decline following yesterday's -14.1% drop.

• The company reported Q1 revenue of $608.1M, missing the $616.9M estimate, alongside an EPS net loss of $0.40/share.
• Investors are reacting to a strategic shift from compounded treatments to lower-margin branded GLP-1s via a Novo Nordisk partnership, prioritized for regulatory stability.
• The selloff continues despite management raising FY2026 revenue guidance to a range of $2.8B–$3.0B.